A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
This is a randomized, double-blind, placebo-controlled phase III study to evaluate GLS-010 plus platinum-containing chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer.
Persistent, Recurrent, or Metastatic Cervical Cancer
DRUG: GLS-010|DRUG: Placebo|DRUG: paclitaxel|DRUG: cisplatin|DRUG: carboplatin|DRUG: bevacizumab
overall survival (OS), OS is defined as the time from randomization to death due to any cause., Up to 2 years
progression-free survival (PFS), PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1., Up to 2 years|Objective Response Rate (ORR), Proportion of subjects who have a complete or partial response relative to baseline based on RECIST 1.1 criteria., Up to 2 years|Duration of Response (DOR), Measured from the date of partial or complete response to therapy until the cancer progresses based on RECIST v1.1 criteria., Up to 2 years|Disease Control Rate (DCR), DCR defined as the proportion of subjects' response of CR, PR, or SD based on RECIST v1.1 criteria., Up to 2 years|Time to Response（TTR）, TTR defined as the time from the date of randomization to the date when the response criteria are first met, based on RECIST v1.1 criteria., Up to 2 years|Number of subjects with adverse events (AEs), An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment, From the time of signed informed consent to 90 days after end of treatment.|Quality of life (QoL), EORTC QLQ-C30 will be used., Up to 2 years
This is a randomized, double-blind, placebo-controlled phase III study，aimed to evaluate the efficacy and safety of GLS-010 plus platinum-containing chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer.All enrolled patients will be randomly divided into 2 groups and continuously treated until any event that meets the criteria for end of the clinical trial.